BioLineRx (BLRX) Revenue & Revenue Breakdown
BioLineRx Revenue Highlights
Latest Revenue (Y)
$4.80M
Latest Revenue (Q)
$6.86M
BioLineRx Revenue by Period
BioLineRx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $4.80M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | -100.00% |
| 2013-12-31 | $113.16M | - |
| 2012-12-31 | $113.16M | 77.06% |
| 2011-12-31 | $63.91M | 100.38% |
| 2010-12-31 | $31.89M | - |
BioLineRx generated $4.80M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
BioLineRx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $6.86M | 42.81% |
| 2023-12-31 | $4.80M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | -100.00% |
| 2010-12-31 | $976.08K | -96.84% |
| 2010-09-30 | $30.92M | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | - |
BioLineRx generated $6.86M in revenue during Q1 2024, up 42.81% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
BioLineRx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARDX | Ardelyx | $333.62M | $98.24M |
| ARQT | Arcutis Biotherapeutics | $196.54M | $30.86M |
| FBIO | Fortress Biotech | $55.13M | $14.63M |
| VRNA | Verona Pharma | $42.28M | $5.62M |
| LXRX | Lexicon Pharmaceuticals | $31.08M | $1.74M |
| IBRX | ImmunityBio | $14.74M | $1.05M |
| VRCA | Verrica Pharmaceuticals | $7.57M | $-1.86M |
| BLRX | BioLineRx | $4.80M | $6.86M |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| CDTX | Cidara Therapeutics | $1.27M | - |
| MCRB | Seres Therapeutics | - | - |
| APTO | Aptose Biosciences | - | - |
| ACHL | Achilles Therapeutics | - | - |
| INZY | Inozyme Pharma | - | - |
| LPTX | Leap Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| MREO | Mereo BioPharma Group | - | - |
| MBIO | Mustang Bio | - | - |